Effects of specific chemical suppressors of plasminogen activator inhibitor-1 in cardiovascular diseases

Bibliography

• East E, Baker D, Pryce G, A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis. Am J Pathol 2005;167:545-54
   PubMed Web of Science ®Google Scholar
• Aso Y. Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci 2007;12:2957-66
   PubMed Web of Science ®Google Scholar
• Westrick RJ, Eitzman DT. Plasminogen activator inhibitor-1 in vascular thrombosis. Curr Drug Targets 2007;8:966-1002
   PubMed Web of Science ®Google Scholar
• Ma LJ, Fogo AB. PAI-1 and kidney fibrosis. Front Biosci 2009;14:2028-41
   Web of Science ®Google Scholar
• Offersen BV, Pfeiffer P, Andreasen P, Overgaard J. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis. Lung Cancer 2007;56:43-50
   PubMed Web of Science ®Google Scholar
• Senoo T, Hattori N, Tanimoto T, Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax 2010;65:334-40
   PubMed Web of Science ®Google Scholar
• Seo JY, Park J, Yu MR, Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta1 during renal fibrosis in diabetes. Am J Nephrol 2009;30:481-90
   PubMed Web of Science ®Google Scholar
• Hu PF, Chen H, Zhong W, Adenovirus-mediated transfer of siRNA against PAI-1 mRNA ameliorates hepatic fibrosis in rats. J Hepatol 2009;51:102-13
   PubMed Web of Science ®Google Scholar
• Alessi MC, Juhan-Vague I. Contribution of PAI-1 in cardiovascular pathology. Arch Mal Coeur Vaiss 2004;97:673-8
   PubMedGoogle Scholar
• Strauss BH, Lau HK, Bowman KA, Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation 1999;100:1616-22
   PubMed Web of Science ®Google Scholar
• Nordt TK, Peter K, Ruef J, Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thromb Haemost 1999;82:14-18
   PubMedGoogle Scholar
• Lundgren CH, Brown SL, Nordt TK, Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996;93:106-10
   PubMed Web of Science ®Google Scholar
• Ha H, Oh EY, Lee HB. The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nat Rev Nephrol 2009;5:203-11
   PubMed Web of Science ®Google Scholar
• Rott D, Leibowitz D, Finci-Yeheskel Z, The relationship of plasminogen activator inhibitor-1 levels to the ST deviation pattern of acute myocardial infarction. Cardiology 2009;112:56-9
   PubMed Web of Science ®Google Scholar
• Meltzer ME, Doggen CJ, de Groot PG, Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. Blood 2010;116:529-36
   PubMed Web of Science ®Google Scholar
• Katsaros KM, Speidl WS, Kastl SP, Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents. J Thromb Haemost 2008;6:508-13
   PubMed Web of Science ®Google Scholar
• Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med 2005;15:254-9
   PubMed Web of Science ®Google Scholar
• Rijneveld AW, Florquin S, Bresser P, Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Blood 2003;103:934-9
   PubMed Web of Science ®Google Scholar
• Chazaud B, Ricoux R, Christov C, Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am J Pathol 2002;160:237-46
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 2004;37:541-8
   PubMed Web of Science ®Google Scholar
• Pauschinger M, Chandrasekharan K, Schultheiss HP. Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system. Heart Fail Rev 2004;9:21-31
   PubMed Web of Science ®Google Scholar
• Heymans S, Pauschinger M, De Palma A, Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation 2006;114:565-73
   PubMed Web of Science ®Google Scholar
• Macfelda K, Weiss TW, Kaun C, Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes. J Mol Cell Cardiol 2002;34:1681-91
   PubMed Web of Science ®Google Scholar
• Suzuki J, Ogawa M, Muto S, A critical role of plasminogen activator inhibitor-1 in the development of neointimal hyperplasia after arterial injury. Expert Opin Ther Targets 2008;12:783-94
   PubMed Web of Science ®Google Scholar
• Suzuki J, Ogawa M, Muto S, A specific inhibitor of plasminogen activator inhibitor-1 suppresses rat autoimmune myocarditis. Expert Opin Ther Targets 2008;12:1313-20
   PubMed Web of Science ®Google Scholar
• Ogawa M, Suzuki J, Yamaguchi Y, The effects of pharmacologic plasminogen activator inhibitor-1 inhibition in acute and chronic rejection in murine cardiac allografts. Transplantation. 27 December 2010. [Epub ahead of print]
   Google Scholar
• Yamaoka N, Kawano Y, Izuhara Y, Structure-activity relationships of new 2-acylamino-3-thiophenecarboxylic acid dimers as plasminogen activator inhibitor-1 inhibitors. Chem Pharm Bull (Tokyo) 2010;58:615-19
   PubMed Web of Science ®Google Scholar
• Izuhara Y, Takahashi S, Nangaku M, Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis. Arterioscler Thromb Vasc Biol 2008;28:672-7
   PubMed Web of Science ®Google Scholar
• Izuhara Y, Yamaoka N, Kodama H, A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J Cereb Blood Flow Metab 2010;30:904-12
   Google Scholar
• Miyazaki H, Ogiku T, Sai H, Design, synthesis, and evaluation of orally active inhibitors of plasminogen activator inhibitor-1 (PAI-1) production. Bioorg Med Chem Lett 2008;18:6419-22
   PubMed Web of Science ®Google Scholar
• Miyazaki H, Sai H, Ohmizu H, Synthesis and evaluation of 1,4-diphenylbutadiene derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) production. Bioorg Med Chem 2010;18:1968-79
   PubMed Web of Science ®Google Scholar
• Elokdah H, Abou-Gharbia M, Hennan JK, Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. J Med Chem 2004;47:3491-4
   PubMed Web of Science ®Google Scholar
• Hennan JK, Elokdah H, Leal M, Evaluation of PAI-039[{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl} (oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther 2005;314:710-16
   PubMed Web of Science ®Google Scholar
• Lijnen HR, Alessi MC, Van Hoef B, On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. J Thromb Haemost 2005;3:1174-9
   PubMed Web of Science ®Google Scholar
• Smith LH, Dixon JD, Stringham JR, Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood 2006;107:132-4
   PubMed Web of Science ®Google Scholar
• Crandall DL, Elokdah H, Di L, Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy. J Thromb Haemost 2004;2:1422-8
   PubMed Web of Science ®Google Scholar
• Crandall DL, Hennan JK, Elokdah H, WAY-140312 reduces plasma PAI-1 while maintaining normal platelet aggregation. Biochem Biophys Res Commun 2003;311:904-8
   PubMed Web of Science ®Google Scholar
• Rupin A, Gaertner R, Mennecier P, S35225 is a direct inhibitor of plasminogen activator inhibitor type-1 activity in the blood. Thromb Res 2008;122:265-70
   PubMed Web of Science ®Google Scholar
• Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, Van De Werf F, Adgey J, Ardissino D, . Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999;354:716-22
   PubMed Web of Science ®Google Scholar
• Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-13
   PubMed Web of Science ®Google Scholar
• Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006;367:569-78
   PubMed Web of Science ®Google Scholar
• Fernández-Avilés F, Alonso JJ, Peña G, ; GRACIA-2 (Groupo de Análisis de Cardiopatía Isquémica Aguda) Investigators. Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. Eur Heart J 2007;28:949-60
   PubMed Web of Science ®Google Scholar
• Marinsek M, Sinkovic A. A randomized trial comparing the effect of ramipril and losartan in survivors of ST-elevation myocardial infarction. J Int Med Res 2009;37:1577-87
   PubMed Web of Science ®Google Scholar
• Walter T, Szabo S, Suselbeck T, Effect of atorvastatin on haemostasis, fibrinolysis and inflammation in normocholesterolaemic patients with coronary artery disease: a post hoc analysis of data from a prospective, randomized, double-blind study. Clin Drug Investig 2010;30:453-60
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18
   PubMed Web of Science ®Google Scholar
• Kato K, Satoh H, Endo Y, Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPAR gamma in endothelial function. Biochem Biophys Res Commun 1999;258:431-5
   PubMed Web of Science ®Google Scholar
• Gottschling-Zeller H, Röhrig K, Hauner H. Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes. Diabetologia 2000;43:377-83
   PubMed Web of Science ®Google Scholar
• Nordt TK, Peter K, Bode C, Sobel BE. Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells. J Clin Endocrinol Metab 2000;85:1563-8
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Chilton RJ. Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us? Diabetes Obes Metab 2010;12:1023-35
   PubMed Web of Science ®Google Scholar
• Kaul S, Bolger AF, Herrington D, Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation 2010;121:1868-77
   PubMed Web of Science ®Google Scholar
• Blauwet LA, Cooper LT. Myocarditis. Prog Cardiovasc Dis 2010;52:274-88
   PubMed Web of Science ®Google Scholar
• Cooper LT Jr. Myocarditis. N Engl J Med 2009;360:1526-38
   PubMed Web of Science ®Google Scholar
• Frustaci A, Chimenti C, Calabrese F, Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 2003;107:857-63
   PubMed Web of Science ®Google Scholar
• Liu PP, Mason JW. Advances in the understanding of myocarditis. Circulation 2001;104:1076-82
   PubMed Web of Science ®Google Scholar
• Kühl U, Pauschinger M, Schwimmbeck PL, Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003;107:2793-8
   PubMed Web of Science ®Google Scholar
• Leimgruber PP, Roubin GS, Hollman J, Restenosis after successful coronary angioplasty in patients with single-vessel disease. Circulation 1986;73:710-17
   PubMed Web of Science ®Google Scholar
• Haude M, Konorza TF, Kalnins U, Heparin-coated stent placement for the treatment of stenoses in small coronary arteries of symptomatic patients. Circulation 2003;107:1265-70
   PubMed Web of Science ®Google Scholar
• Holmes DR Jr. In-stent restenosis. Rev Cardiovasc Med 2001;2:115-19
   PubMedGoogle Scholar
• Danzi GB, Sesana M, Capuano C, Restenosis after NIR stent implantation. Minerva Cardioangiol 2002;50:455-62
   PubMedGoogle Scholar
• Sata M, Saiura A, Kunisato A, Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002;8:403-9
   PubMed Web of Science ®Google Scholar
• Ibarra CA, Blouse GE, Christian TD, Shore JD. The contribution of the exosite residues of plasminogen activator inhibitor-1 to proteinase inhibition. J Biol Chem 2004;279:3643-50
   PubMed Web of Science ®Google Scholar
• Weisberg AD, Albornoz F, Griffin JP, Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol 2005;25:365-71
   PubMed Web of Science ®Google Scholar
• Benza RL, Grenett HE, Bourge RC, Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease. Circulation 1998;98:2248-54
   PubMed Web of Science ®Google Scholar
• Benza RL, Anderson PG, Lyle K, Donor PAI-1 expression inhibits the intimal response of early allograft vascular disease. J Heart Lung Transplant 2003;22:515-18
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Moons L, Lijnen R, Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation. Circulation 1997;96:3180-91
   PubMed Web of Science ®Google Scholar